Scarica l'app Stockscreener
5.03
9.83%
0.45
Dopo l'orario di chiusura:
5.13
0.10
+1.99%
Precedente Chiudi:
$4.58
Aprire:
$4.6
Volume 24 ore:
1.40M
Relative Volume:
1.08
Capitalizzazione di mercato:
$342.97M
Reddito:
-
Utile/perdita netta:
$-64.20M
Rapporto P/E:
-2.3395
EPS:
-2.15
Flusso di cassa netto:
$57,000
1 W Prestazione:
+34.13%
1M Prestazione:
+164.74%
6M Prestazione:
+272.59%
1 anno Prestazione:
+168.98%
Intervallo 1D:
$4.5808
$5.19
Intervallo di 1 settimana:
$3.46
$5.19
Portata 52W:
$1.05
$5.19
Climb Bio Inc Stock (CLYM) Company Profile
Nome
Climb Bio Inc
Settore
Industria
Telefono
1-866-857-2596
Indirizzo
20 WILLIAM STREET, WELLESLEY HILLS
Confronta CLYM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
5.03 | 312.28M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Iniziato | William Blair | Outperform |
| 2025-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-08-15 | Iniziato | Robert W. Baird | Outperform |
| 2025-06-06 | Iniziato | Oppenheimer | Outperform |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Climb Bio Inc Borsa (CLYM) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO) - The Globe and Mail
Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch - TipRanks
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - Sahm
Is Climb Bio Inc. stock oversold or undervaluedProfit Target & Low Risk High Reward Ideas - ulpravda.ru
How Climb Bio Inc. stock reacts to oil pricesTreasury Yields & Free Weekly Watchlist of Top Performers - ulpravda.ru
Climb Bio advances clinical trials with first patients dosed in key studies - Investing.com Australia
Climb Bio outlines 2026 clinical milestones and cash runway - TipRanks
Climb Bio advances clinical trials with first patients dosed in key studies By Investing.com - Investing.com South Africa
Climb Bio reports inducement grant under Nasdaq listing rule - MSN
Climb Bio, Inc.Common Stock (NQ: CLYM - markets.financialcontent.com
Climb Bio (CLYM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Climb Bio Inc Stock Analysis and ForecastSector Performance Review & Explosive Capital Growth Plans - earlytimes.in
Setup Watch: Will SBUX stock benefit from commodity pricesPortfolio Value Summary & AI Driven Price Forecasts - moha.gov.vn
Alumis issues breach notice to Climb Bio over $3 million milestone payment - Investing.com Nigeria
Climb Bio appoints Edgar D. Charles as Chief Medical Officer - MSN
Alumis IncCo & Its Unit Issues Notice Of Material Breach & Notification Of Claim For Indemnification To Climb BioSEC Filing - TradingView — Track All Markets
Alumis issues breach notice to Climb Bio over $3 million milestone payment By Investing.com - Investing.com South Africa
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Climb Bio challenges Alumis milestone and royalty obligations - MSN
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Climb Bio files complaint against Alumis and AcelyrinSEC filing - MarketScreener
Climb Bio Challenges Alumis Milestone and Royalty Obligations - TipRanks
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks - Insider Monkey
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio's (CLYM) Budoprutug Across Clinical Tracks - Finviz
Climb Bio initiated with a buy at Freedom Capital - MSN
Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target - Investing.com Canada
Climb Bio initiated with a Buy at Freedom Capital - TipRanks
Apollo Tyres Limited Stock Poised for Technical ComebackTrading Psychology Tips & Outstanding Investment Portfolio - bollywoodhelpline.com
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Yahoo Finance
Climb Bio price target raised to $11 from $9 at HC Wainwright - MSN
Retail investors in Climb Bio, Inc. (NASDAQ:CLYM) are its biggest bettors, and their bets paid off as stock gained 15% last week - simplywall.st
Vilin Bio Med Limited Breaks Losing Streak — Is the Trend ReversingStock Split Announcements & Rapid Wealth Accumulation - bollywoodhelpline.com
AI Indicators Detect Buy Opportunity in Shree OSFM ESupport and Resistance Levels & Build a Smarter Portfolio Right Now - bollywoodhelpline.com
Candlestick Signal Suggests Reversal in Rajputana Industries LimitedTechnical Resistance Breaks & Accelerated Capital Growth - bollywoodhelpline.com
HC Wainwright Reduces Earnings Estimates for Climb Bio - MarketBeat
Can Climb Bio Inc. stock deliver sustainable ROE2025 Growth vs Value & Consistent Profit Trade Alerts - Улправда
Climb Bio Earnings Notes - Trefis
Climb Bio Inc. (CLYM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why analysts upgrade Climb Bio Inc. stockMarket Sentiment Report & Technical Pattern Based Buy Signals - DonanımHaber
Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
H.C. Wainwright raises Climb Bio stock price target to $11 on budoprutug progress - Investing.com Canada
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
HC Wainwright & Co. Raises Climb Bio (CLYM) Price Target to $11. - GuruFocus
HC Wainwright & Co. Maintains Climb Bio (CLYM) Buy Recommendation - Nasdaq
Climb Bio price target raised to $11 from $9 at H.C. Wainwright - TipRanks
Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ra Capital Management, L.P. Buys 101,462 Shares of Climb Bio (NASDAQ:CLYM) Stock - Defense World
Climb Bio Stock 7-Day Winning Spree: Stock Climbs 169% - Trefis
Climb Bio Soars Amid Strategic Move and Market Optimism - timothysykes.com
Climb Bio Inc Azioni (CLYM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Climb Bio Inc Azioni (CLYM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Dec 11 '25 |
Buy |
2.18 |
213,099 |
464,556 |
3,294,856 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Dec 12 '25 |
Buy |
2.86 |
101,462 |
290,181 |
3,396,318 |
| Brennan Aoife | President and CEO |
Jun 30 '25 |
Sale |
1.22 |
20,618 |
25,154 |
48,132 |
| Pimblett Emily | SVP, Finance & CAO |
Jun 20 '25 |
Sale |
1.24 |
1,242 |
1,540 |
18,888 |
| Pimblett Emily | SVP, Finance & CAO |
Mar 20 '25 |
Sale |
1.31 |
1,199 |
1,571 |
15,130 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):